TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ICCC

ImmuCell Corporation

Healthcare · Biotechnology

10.00$ -0.3% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement ICCC
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
41.4% 38.9% 43.2% 49.9% 52.7% 50.9% 55.3% 55.0% 58.8% 74.8% 70.0% 58.6%
58.6% 61.1% 56.8% 50.1% 47.3% 49.1% 44.7% 45.0% 41.2% 25.2% 30.0% 41.4%
28.7% 12.1% 13.0% 19.6% 32.0% 26.9% 28.4% 21.7% 24.2% 25.2% 14.7% 11.0%
15.3% 12.6% 15.2% 14.6% 15.8% 12.3% 11.2% 9.0% 12.2% 12.2% 8.4% 11.6%
61.3% 40.4% 47.5% 52.4% 66.8% 56.1% 53.7% 43.6% 53.6% 58.1% 36.2% 35.4%
-2.7% 20.7% 9.3% -2.3% -13.2% -7.0% -9.0% 1.3% -12.4% -32.9% -6.2% 6.0%
0.8% 0.8% 1.7% 2.1% 3.9% 3.1% 2.7% 1.6% 1.8% 2.6% 2.1% 1.6%
-3.4% 20.2% 7.9% -4.2% -16.9% -9.2% -6.7% -0.4% -13.4% -33.0% -8.1% -3.7%
-1.2% 8.3% 2.6% -2.6% 4.2% 0.2% -0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
-2.2% 11.9% 5.3% -1.6% -21.1% -9.4% -6.7% -0.4% -13.4% -33.1% -8.1% -3.8%
3.3% 25.9% 18.0% 6.3% 0.8% 9.6% 6.3% 14.0% 1.0% -14.3% 4.0% 7.7%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?